Global Radiation Therapy for Brain Tumors Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Radiation Therapy for Brain Tumors Market Size

• The global radiation therapy for brain tumors market size was valued at USD 1.51 billion in 2025and is expected to reach USD 2.90 billion by 2033, at a CAGR of 8.5% during the forecast period
• The market growth is primarily driven by the rising incidence of brain tumors, increasing prevalence of metastatic cancers affecting the brain, and growing demand for precise, non-invasive treatment modalities
• In addition, continuous advancements in radiation delivery technologies, expanding adoption of image-guided and stereotactic radiosurgery systems, and increasing integration of AI in treatment planning are significantly improving clinical outcomes and accelerating market expansion

Radiation Therapy for Brain Tumors Market Analysis

• Radiation therapy for brain tumors plays a critical role in modern neuro-oncology, offering targeted tumor control while preserving surrounding healthy brain tissue through high-precision radiation delivery techniques
• The increasing burden of both primary brain tumors and brain metastases from cancers such as lung, breast, and melanoma is a key factor driving demand for advanced radiation therapy solutions
• North America dominated the radiation therapy for brain tumors market with a market share of 42.6% share in 2025, supported by advanced healthcare infrastructure, strong adoption of cutting-edge radiation technologies, and high availability of specialized oncology care
• Asia-Pacific is expected to be the fastest growing region in the radiation therapy for brain tumors market during the forecast period due to improving cancer care infrastructure, rising healthcare investments, and increasing awareness of early cancer diagnosis and treatment
• External Beam Radiation Therapy (EBRT) dominated the radiation therapy for brain tumors market due to its widespread clinical use, versatility across tumor types, and continuous technological enhancements in precision and targeting

Report Scope and Radiation Therapy for Brain Tumors MarketSegmentation

Radiation Therapy for Brain Tumors Market Trends

“Shift Toward Precision, Image-Guided, and AI-Integrated Radiation Systems”

• A key trend in the market is the increasing shift toward highly precise, image-guided, and AI-assisted radiation therapy systems designed to maximize tumor targeting while minimizing damage to healthy brain tissue
• Technologies such as Gamma Knife, CyberKnife, and proton therapy systems are gaining traction due to their ability to deliver highly focused radiation doses with sub-millimeter accuracy
• Integration of MRI-guided radiation therapy systems is enabling real-time tumor tracking and adaptive treatment planning, improving clinical outcomes in complex brain tumor cases
• Growing adoption of stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) is reducing treatment durations while improving patient convenience and recovery time
• The trend toward non-invasive, outpatient-based radiation treatments is reshaping patient care models in neuro-oncology

Radiation Therapy for Brain Tumors Market Dynamics

Driver

“Rising Incidence of Brain Tumors and Advancements in Radiation Technology”

• The increasing incidence of primary and metastatic brain tumors is a major factor driving demand for advanced radiation therapy solutions globally
• Continuous technological advancements in LINAC systems, proton therapy, and stereotactic radiosurgery are improving treatment accuracy and survival outcomes
• Growing preference for non-invasive treatment modalities over traditional surgical interventions is accelerating adoption
• Expanding healthcare infrastructure and rising oncology expenditure are further supporting market growth
• Increasing awareness of early diagnosis and improved access to cancer care are contributing to higher treatment rates

Restraint/Challenge

“High Treatment Costs and Limited Access to Advanced Systems”

• The high cost associated with advanced radiation therapy systems such as proton therapy and CyberKnife systems limits widespread adoption, particularly in developing regions
• Limited availability of specialized oncology centers restricts access to advanced brain tumor radiation treatments
• Complex installation and maintenance requirements of high-end radiation systems increase operational costs for healthcare providers
• Shortage of skilled radiation oncologists and medical physicists poses additional challenges to optimal treatment delivery
• Reimbursement limitations in certain regions further restrict patient access to advanced therapies

Radiation Therapy for Brain Tumors Market Scope

The market is segmented on the basis of therapy type, technology type, tumor type, and end user.

• By Therapy Type

On the basis of therapy type, the global radiation therapy for brain tumors market is segmented into external beam radiation therapy (EBRT), internal radiation therapy (brachytherapy), and systemic radiation therapy. The EBRT segment dominated the market, driven by its widespread clinical adoption, non-invasive treatment approach, and high precision in targeting both primary and metastatic brain tumors. EBRT remains the standard of care in neuro-oncology due to its ability to deliver controlled radiation doses while minimizing damage to surrounding healthy brain tissues. its dominance is further supported by extensive use of advanced techniques such as IMRT, IGRT, and stereotactic radiosurgery across hospitals and cancer centers globally.

The systemic radiation therapy segment is expected to witness the fastest growth during the forecast period, driven by increasing research and development in targeted radionuclide therapies and molecularly guided radiation approaches for metastatic brain tumors. although still in early clinical adoption in neuro-oncology, advancements in radiopharmaceuticals and precision oncology are expanding its potential therapeutic applications, particularly for patients with widespread metastatic disease where conventional localized radiation has limitations.

• By Technology Type

On the basis of technology type, the global radiation therapy for brain tumors market is segmented into linear accelerators (LINAC), gamma knife systems, cyberknife systems, proton therapy systems, tomotherapy systems, mri-guided radiation therapy systems, and particle beam systems (proton/heavy ion). In 2025, the linear accelerators (LINAC) segment dominated the market, driven by its widespread availability, cost-effectiveness, and versatility in treating a wide range of brain tumor cases. LINAC systems are widely used across hospitals and oncology centers due to their ability to support multiple advanced treatment modalities such as IMRT, IGRT, and stereotactic radiosurgery, making them the backbone of radiation oncology infrastructure globally.

The proton therapy systems segment is expected to witness the fastest growth during the forecast period, driven by increasing demand for highly precise radiation delivery with minimal exposure to surrounding healthy brain tissues. Proton therapy is gaining strong adoption in advanced oncology centers due to its bragg peak property, which enables superior dose localization. rising investments in cancer treatment infrastructure, particularly in developed economies and select emerging markets, along with growing clinical evidence supporting improved outcomes in pediatric and complex brain tumor cases, are accelerating segment growth.

• By Tumor Type

On the basis of tumor type, the global radiation therapy for brain tumors market is segmented into primary brain tumors and secondary (metastatic) brain tumors. the primary brain tumors segment dominated the market with the largest revenue share in 2025, driven by the high prevalence of gliomas, meningiomas, and astrocytomas, which require long-term and highly targeted radiation therapy. Radiation therapy plays a central role in both definitive and adjuvant treatment settings, especially when surgical intervention is incomplete or not feasible, thereby sustaining consistent demand across neuro-oncology care pathways.

The secondary (metastatic) brain tumors segment is expected to witness the fastest growth during the forecast period, driven by the rising incidence of systemic cancers such as lung, breast, melanoma, and colorectal cancers that frequently metastasize to the brain. Increasing overall cancer survival rates are also contributing to a higher number of patients developing brain metastases. the growing preference for stereotactic radiosurgery and advanced targeted radiation techniques for multiple lesion management is further accelerating segment expansion.

• By End User

On the basis of end user, the global radiation therapy for brain tumors market is segmented into hospitals, specialty cancer centers / oncology clinics, academic & research institutes, and ambulatory radiotherapy centers. The hospitals segment dominated the market with the largest revenue share in 2025, driven by high patient inflow, availability of comprehensive oncology infrastructure, and integration of multidisciplinary cancer care services. hospitals serve as primary treatment centers for both emergency and planned radiation therapy procedures, making them the key hub for brain tumor management.

The specialty cancer centers / oncology clinics segment is expected to witness the fastest growth during the forecast period, driven by increasing demand for highly specialized and precision-based radiation therapies such as stereotactic radiosurgery, proton therapy, and adaptive radiation techniques. These centers are increasingly preferred for complex brain tumor cases due to their advanced technology adoption, skilled oncology specialists, and ability to deliver personalized treatment plans, which significantly improve patient outcomes.

Radiation Therapy for Brain Tumors Market Regional Analysis

• North America dominated the global radiation therapy for brain tumors market with the largest revenue share of 42.6% in 2025, due to advanced oncology infrastructure, high adoption of cutting-edge radiation technologies, and strong presence of leading medical device manufacturers
• Strong reimbursement frameworks and favorable healthcare policies across the region further support widespread adoption of advanced radiation therapy systems for brain tumors, improving patient access to high-cost treatments
• High prevalence of brain tumors and metastatic cancers, along with increasing demand for minimally invasive and precision-based treatment options, is significantly driving market growth across hospitals and specialty oncology centers in the region

U.S. Radiation Therapy for Brain Tumors Market Insight

The U.S. radiation therapy for brain tumors market held the dominant position within North America, accounting for the majority of regional revenue share in 2025, driven by a high prevalence of primary brain tumors and brain metastases, along with strong access to advanced oncology care. The country benefits from widespread adoption of cutting-edge technologies such as LINAC-based systems, Gamma Knife, CyberKnife, and proton therapy, supported by well-established cancer treatment infrastructure and leading medical device manufacturers. In addition, favorable reimbursement policies, high healthcare expenditure, and growing use of precision and image-guided radiation therapies are further strengthening market growth in the U.S.

Europe Radiation Therapy for Brain Tumors Market Insight

The Europe radiation therapy for brain tumors market is witnessing steady growth, driven by rising incidence of primary and metastatic brain tumors, increasing aging population, and strong emphasis on early cancer diagnosis and advanced treatment adoption. The region benefits from well-established healthcare systems, widespread availability of LINAC-based radiotherapy, and growing use of advanced technologies such as Gamma Knife, CyberKnife, and proton therapy in specialized oncology centers. Supportive government healthcare policies, favorable reimbursement structures, and increasing investment in cancer care infrastructure are further contributing to market expansion across key countries such as Germany, the U.K., France, and Italy.

U.K. Radiation Therapy for Brain Tumors Market Insight

The U.K. radiation therapy for brain tumors market is experiencing steady growth, supported by strong national healthcare programs, rising incidence of brain tumors, and increasing focus on early cancer detection and treatment. The presence of a well-developed public healthcare system through the NHS ensures broad access to advanced radiation therapy services, including LINAC-based systems and stereotactic radiosurgery technologies such as Gamma Knife and CyberKnife. Growing adoption of precision oncology, increasing use of outpatient-based radiotherapy, and expanding availability of specialized cancer centers are further strengthening market growth across the country.

Germany Radiation Therapy for Brain Tumors Market Insight

The Germany radiation therapy for brain tumors market is growing steadily, driven by a high burden of cancer cases, strong aging population base, and increasing adoption of advanced radiation oncology technologies. The country is well known for its advanced healthcare infrastructure and strong emphasis on precision medicine, supporting widespread use of LINAC-based systems, stereotactic radiosurgery (Gamma Knife and CyberKnife), and emerging proton therapy solutions in specialized cancer centers. High investment in medical technology innovation, strong clinical research ecosystem, and structured reimbursement framework are further supporting market expansion across hospitals and oncology clinics in Germany.

Asia-Pacific Radiation Therapy for Brain Tumors Market Insight

The Asia-Pacific radiation therapy for brain tumors market is witnessing the fastest growth, driven by rising incidence of brain tumors, increasing burden of metastatic cancers, and improving access to advanced oncology care across emerging economies. Rapid urbanization, growing exposure to risk factors such as pollution, and expanding healthcare infrastructure are further supporting market adoption. Countries such as China, India, and Japan are increasingly investing in LINAC-based systems, stereotactic radiosurgery technologies, and proton therapy centers to enhance cancer treatment capabilities. In addition, rising healthcare expenditure, government initiatives to strengthen oncology services, and growing awareness of early cancer diagnosis are significantly accelerating regional market expansion.

Japan Radiation Therapy for Brain Tumors Market Insight

The Japan radiation therapy for brain tumors market is expanding steadily, supported by a high aging population, increasing incidence of brain tumors, and strong demand for advanced cancer treatment solutions. The country has a highly developed healthcare system with widespread adoption of precision radiation technologies such as LINAC-based systems, Gamma Knife, CyberKnife, and MRI-guided radiation therapy in specialized oncology centers. Japan’s strong focus on technological innovation, early diagnosis, and minimally invasive treatment approaches is further driving the uptake of advanced stereotactic radiosurgery and proton therapy systems. In addition, integration of robotics and image-guided therapy in cancer care is strengthening treatment accuracy and improving patient outcomes across the country.

India Radiation Therapy for Brain Tumors Market Insight

The India radiation therapy for brain tumors market is growing rapidly, driven by rising incidence of brain tumors, increasing burden of metastatic cancers, and improving access to advanced oncology care across urban and semi-urban regions. Expanding healthcare infrastructure, growing awareness of early cancer diagnosis, and increasing affordability of treatment are supporting wider adoption of radiation therapy technologies, particularly LINAC-based systems in hospitals and cancer centers. Government initiatives to strengthen cancer care services, along with rapid expansion of private oncology chains and specialty hospitals, are further accelerating market growth. In addition, increasing availability of cost-effective stereotactic radiosurgery and growing investment in proton therapy facilities are expected to significantly enhance treatment capabilities in the country over the forecast period.

Radiation Therapy for Brain Tumors Market Share

The Radiation therapy for brain tumors industry is primarily led by well-established companies, including:

• Varian Medical Systems, Inc. - A Siemens Healthineers Company (U.S.)
• Elekta AB (Sweden)
• Mevion Medical Systems (U.S.)
• Hitachi Ltd. (Japan)
• Brainlab AG (Germany)
• Toshiba Medical Systems (Japan)
• Canon Medical Systems Corporation (Japan)
• GE HealthCare (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Mitsubishi Electric Corporation (Japan)
• Nordion Inc. (Canada)
• Shinva Medical Instrument Co., Ltd. (China)

What are the Recent Developments in Global Radiation Therapy for Brain Tumors Market?

• In July 2025, Elekta AB received regulatory and product innovation momentum through continued expansion of its precision radiation therapy portfolio, including advanced linear accelerator and MRI-guided radiotherapy systems, supporting more precise and adaptive treatment for brain tumor patients, as reported in its official press release updates and market communications
• In January 2025, Accuray Incorporated received NMPA approval for Radixact Sync and CyberKnife S7 systems, advancing its stereotactic radiosurgery portfolio for high-precision, minimally invasive brain tumor radiation therapy
• In September 2025, Accuray launched the Accuray Stellar solution based on the Radixact platform, designed to enhance adaptive radiotherapy and improve clinical workflow efficiency in complex cancer and brain tumor treatment settings
• In 2026, Elekta announced new product and strategic updates including advancements in LINAC-based and stereotactic radiotherapy systems, strengthening its position in precision oncology and brain tumor treatment technologies

SKU-76083